ℹ️
🇬🇧
Search
Search for publications relevant for "factor Xa inhibitors"
factor Xa inhibitors
Publication
Class
Person
Publication
Programmes
publication
Direct factor Xa inhibitor rivaroxaban
2009 |
Faculty of Medicine in Hradec Králové
publication
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
2008 |
First Faculty of Medicine
publication
Rivaroxaban - a newly marketed antithrombotic agent
2009 |
First Faculty of Medicine
publication
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
+1
2008 |
Faculty of Medicine in Hradec Králové
publication
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
2008 |
Second Faculty of Medicine
publication
Anticoagulation 2013
2013 |
Faculty of Medicine in Hradec Králové
publication
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
2014 |
Publication without faculty affiliation
publication
Apixabans
2011 |
First Faculty of Medicine, Third Faculty of Medicine
publication
Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial
2007 |
First Faculty of Medicine
publication
Randomized, Double-Blind, Dose-Ranging Sudy of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. The SEPIA-PCI Trial
2007 |
Faculty of Physical Education and Sport
publication
Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients
2020 |
Faculty of Medicine in Hradec Králové
publication
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
2009 |
Third Faculty of Medicine
publication
Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
2017 |
First Faculty of Medicine
publication
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
2011 |
Publication without faculty affiliation
publication
Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty
2008 |
Central Library of Charles University
publication
Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty
2008 |
Faculty of Medicine in Pilsen
publication
Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty
2008 |
First Faculty of Medicine, Faculty of Medicine in Pilsen
publication
Commentary on Aristotle study (Apixaban compared with warfarin in patients with atrial fibrillation)
2011 |
First Faculty of Medicine
publication
Pharmacological prevention of thrombembolic disease - part 2
2011 |
Central Library of Charles University, First Faculty of Medicine
publication
Pharmacological prevention of thrombembolic disease - part 1
2011 |
Central Library of Charles University, First Faculty of Medicine
publication
What we expect from anticoagulant therapy in 2014
2014 |
Publication without faculty affiliation
publication
Low molecular weight heparins - their significance in current practice
2011 |
Central Library of Charles University, Third Faculty of Medicine
publication
Consensus recommendations for the prophylaxis of venous thrombosis after total joint replacement (TEP) of the hip or knee
Publication without faculty affiliation
publication
Anticoagulation therapy in 2015
2015 |
First Faculty of Medicine
publication
Anticoagulation therapy in 2015
2016 |
Publication without faculty affiliation
publication
New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs
2011 |
Faculty of Medicine in Hradec Králové
publication
Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study
2013 |
Publication without faculty affiliation
publication
Apixaban has been available for the treatment of venous thromboembolic disease for more than two years
+1
2017 |
First Faculty of Medicine, Third Faculty of Medicine